Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 94, Issue 2, 2011, Pages 255-261

  Mishra, Manish ^a,b   Kumar, Hemant ^a   Bajpai, Surabhi ^b   Singh, Rakesh K ^b   Tripathi, Kamlakar ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Cardiovascular complications; Endothelial dysfunction; HsCRP; IL 12; IL 6

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 6; LIPID; NITRIC OXIDE; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FAMILY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; UNITED STATES;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HUMANS; INDIA; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-12; INTERLEUKIN-6; LINEAR MODELS; LIPIDS; MIDDLE AGED; NITRIC OXIDE; RISK ASSESSMENT; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 81255157815     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.07.037     Document Type: Article

References (27)

1. Zou M.H., Cohen R., Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium 2004, 11:89-97.
2. Nyström T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res 2008, 40:593-606.
3. Venkatapuram S., Shannon R.P. Managing atherosclerosis in patients with type 2 diabetes mellitus and metabolic syndrome. Am J Ther 2006, 13:64-71.
4. Bakker W., Eringa E.C., Sipkema P., van Hinsbergh V.W. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res 2009, 335:165-189.
5. Constans J., Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 2006, 368:33-47.
6. Vijay S.K., Mishra M., Kumar H., Tripathi K. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol 2009, 46:27-33.
7. Versari D., Daghini E., Virdis A., Ghiadoni L., Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009, 32(Suppl. 2):S314-S321.
8. Hauer A.D., Vyttenhore C., de Vos P., Stroobant V., Renauld I.C., van Berkel T.I.C. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 2005, 112:1054-1062.
9. Wegner M., Winiarska H., Bobkiewicz-Kozłowska T., Dworacka M. IL-12 serum levels in patients with type 2 diabetes treated with sulphonylureas. Cytokine 2008, 42:312-316.
10. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl. 1):S62-S69.
11. The Oxford Centre for Diabetes, Endocrinology & Metabolism: Diabetes Trial Unit HOMA Calculator 2004, Available from http://www.dtu.ox.ac.uk/ [online].
12. Ghasemi A., Zahedi Asl S., Mehrabi Y., Saadat N., Azizi F. Serum nitric oxide metabolite levels in a general healthy population: relation to sex and age. Life Sci 2008, 83:326-331.
13. Mallika V., Goswami B., Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology 2007, 58:513-522.
14. Miyazaki Y., DeFronzo R.A. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008, 10:1204-1211.
15. Snehalatha C., Ramachandran A. Cardiovascular risk factors in the normoglycaemic Asian-Indian population-influence of urbanization. Diabetologia 2009, 52:596-599.
16. Winkler K., Winkelmann B.R., Scharnagl H., Hoffmann M.M., Grawitz A.B., Nauck M., et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005, 111:980-987.
17. van der Velde A.E. Reverse cholesterol transport: from classical view to new insights. World J Gastroenterol 2010, 16:5908-5915.
18. Singh B., Arora S., Goswami B., Mallika V. Metabolic syndrome: a review of emerging markers and management. Diabetes Metab Syndr Clin Res Rev 2009, 3:240-254.
19. Ridker P.M. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007, 65:S253-S259.
20. Hajer G.R., van Haeften T.W., Visseren F.L.J. Adipose tissue dysfunction in obesity, diabetes and vascular diseases. Eur Heart J 2008, 29:2959-2971.
21. Meigs J.B., Hu F.B., Rifai N., Manson J.E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004, 291:1978-1986.
22. Song Y., Manson J.E., Tinker L., Rifai N., Cook N.R., Hu F.B., et al. Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women. Diabetes 2007, 56:1898-1904.
23. Schmidt C., Hulthe J., Fagerberg B., Baseline ICAM-1 VCAM-1 are increased in initially healthy middle-aged men who develop cardiovascular disease during 6.6 years of follow-up. Angiology 2009, 60:108-114.
24. Gewaltig M.T., Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 2002, 55:250-260.
25. Thorand B., Baumert J., Chambless L., Meisinger C., Kolb H., Döring A., et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 2006, 26:398-405.
26. von der Thüsen J.H., Kuiper J., van Berkel T.J., Biessen E.A. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 2003, 55:133-166.
27. Silswal N., Singh A.K., Aruna B., Mukhopadhyay S., Ghosh S., Ehtesham N.Z. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappa B-dependent pathway. Biochem Biophys Res Commun 2005, 344:1092-1101.